Kezar Life Sciences, Inc. Common Stock (KZR) is a publicly traded Healthcare sector company. As of May 21, 2026, KZR trades at $7.29 with a market cap of $53.86M and a P/E ratio of -0.95. KZR moved -0.82% today. Year to date, KZR is +14.80%; over the trailing twelve months it is +76.94%. Its 52-week range spans $3.53 to $9.18. Analyst consensus is neutral with an average price target of $7.00. Rallies surfaces KZR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kezar Life Sciences Sale to Aurinia at $6.955 Sparks Fiduciary Duty Probe: An investor rights law firm is investigating Kezar Life Sciences' sale to Aurinia Pharmaceuticals at $6.955 per share plus one non-transferable contingent value right for potential breaches of fiduciary duty. Shareholders may pursue increased consideration or additional disclosures on a contingent fee basis covering legal expenses only upon recovery.
| Metric | Value |
|---|---|
| Price | $7.29 |
| Market Cap | $53.86M |
| P/E Ratio | -0.95 |
| EPS | $-7.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.18 |
| 52-Week Low | $3.53 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-56.03M |
| Gross Margin | 0.00% |
1 analysts cover KZR: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.00.